Utilisation of MHCII Variant Mice for Antibody Discovery

GSK is committed to the replacement, reduction and refinement of animal studies (3Rs). Non-animal models and alternative technologies are part of our strategy and employed where possible. When animals are required, application of robust study design principles and peer review minimises animal use, reduces harm and improves benefit in studies.

All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare, and Treatment of Animals.

Author: Kajtar, Lewis; Industrial Supervisor: Percival-Alwyn, Jennifer, Academic supervisor: Rattray, Zahra

1. Purpose

- Identification of MHCII variants modulating antibody discovery in terms of:
 - Affinity
 - **Epitope Diversity**
 - Developability
- Investigation of *in-vivo* antibody discovery using mouse models

2. Major Histocompatibility Complex (MHC) II


- Expressed on the surface of antigen presenting cells
- Activate T helper cells by binding exogenous antigens
- Critical for induction of the antibody response
- Many MHCII variants
 - Mostly vary in the **peptide binding cleft**
 - Vary in their ability to bind peptides
 - Therefore, differ in ability to activate T-helper cells and the antibody response





- Immunisation of Next Generation Transgenic Mice expressing humanised antibodies for antibody discovery
- Mice generated expressing humanised antibodies AND differing MHCII variants: 'Variants 1-3'
- Compensate for MHCII variation in antibody discovery

peptide binding cleft



intracellular

Serum Titres

- **Serum titres** demonstrate **MHCII** variant modulation of antibody responses
- Variant 3 enhances target specific serum titres
- Serum titres against challenging 4-pass TM target 800000-600000specific 400000-200000-Individual mice
- N=1 observation
- MHCII heterozygous mice utilised for availability

5. MHCII Variant Sequences

- Peptide
 - 2 amino acid **deletion** in *variant 3* β chain
 - Numerous amino acid **substitutions** across both chains
 - Substitutions for amino acids with substantially different characteristics

MHCII variant β chain	Variant 1	Variant 2	Variant 3
Variant 1		90.2	84.3
Variant 2	90.2		84.3
Variant 3	84.3	84.3	

Variations likely modulate antigen binding

6. To conclude,

- MHCII is critical for activation of the antibody response
 - Modulation by MHCII variation
- MHCII haplotype mice incorporate MHCII variation

More to come!

Positive observations are already being made



